Alpha 2.0
Login Register
» Articles » PMID: 29218818

Loss of Fundus View As an Indication for Secondary Enucleation in Retinoblastoma

Overview
Journal Pediatr Blood Cancer
Specialties Hematology
Oncology
Pediatrics
Date 2017 Dec 9
PMID 29218818
Citations 4
Authors
Jesse L Berry
Kaitlin Kogachi
Rima Jubran
Jonathan W Kim
Affiliations
Soon will be listed here.
Abstract

In this retrospective study, we evaluated loss of fundus view as an indication for secondary enucleation and associated histopathologic findings. Of 64 secondarily enucleated eyes, 24 were enucleated for loss of fundus view. Average time from loss of fundus view to enucleation was 4.7 months. Of these eyes, 22 had viable tumor cells on histopathology, but none had high-risk features. Loss of fundus view was a common indication for secondary enucleation after chemoreduction. Given the high prevalence of viable histopathologic tumor cells, enucleation for loss of fundus view should not be significantly delayed to decrease risk of high-risk tumor progression.

Citing Articles

Management of Intraocular Retinoblastoma: ICMR Consensus Guidelines.

Meel R, Kulkarni S, Singh L, Chinnaswamy G, Radhakrishnan V, Madan R Indian J Pediatr. 2024; 91(11):1166-1176.

PMID: 38609685 DOI: 10.1007/s12098-024-05095-0.

Intra-Arterial Chemotherapy as Primary Treatment for Advanced Unilateral Retinoblastoma in China.

Liang T, Zhang X, Li J, Hua X, Zhao P, Ji X Front Med (Lausanne). 2022; 9:855661.

PMID: 35462996 PMC: 9021594. DOI: 10.3389/fmed.2022.855661.

Current Indications of Secondary Enucleation in Retinoblastoma Management: A Position Paper on Behalf of the European Retinoblastoma Group (EURbG).

Stathopoulos C, Lumbroso-Le Rouic L, Moll A, Parulekar M, Maeder P, Doz F Cancers (Basel). 2021; 13(14).

PMID: 34298608 PMC: 8303810. DOI: 10.3390/cancers13143392.

Posterior Vitreous Detachment and the Associated Risk of Retinal Toxicity with Intravitreal Melphalan Treatment for Retinoblastoma.

Berry J, Lee R, Patel L, Le B, OFee J, Jubran R Ocul Oncol Pathol. 2019; 5(4):238-244.

PMID: 31367584 PMC: 6615322. DOI: 10.1159/000493687.

References
1.
Berry J, Jubran R, Kim J, Wong K, Bababeygy S, Almarzouki H . Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer. 2012; 60(4):688-93. DOI: 10.1002/pbc.24303. View
2.
Murphree A . Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005; 18(1):41-53, viii. DOI: 10.1016/j.ohc.2004.11.003. View
3.
Zhao J, Dimaras H, Massey C, Xu X, Huang D, Li B . Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J Clin Oncol. 2011; 29(7):845-51. DOI: 10.1200/JCO.2010.32.5332. View
4.
Fabian I, Stacey A, Chowdhury T, Duncan C, Karaa E, Scheimberg I . High-Risk Histopathology Features in Primary and Secondary Enucleated International Intraocular Retinoblastoma Classification Group D Eyes. Ophthalmology. 2017; 124(6):851-858. DOI: 10.1016/j.ophtha.2017.01.048. View
5.
Gunduz K, Gunalp I, Yalcindag N, Unal E, Tacyildiz N, Erden E . Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation. Ophthalmology. 2004; 111(10):1917-24. DOI: 10.1016/j.ophtha.2004.04.016. View